News By Tag
News By Location
Pioneering HIV Researcher Recipient of Prestigious Patient Impact Research Award
St. Clair is being honored for discovering AZT as a treatment for HIV. On a Friday afternoon in November 1984, she was testing the effect of AZT, a compound developed as a potential treatment for leukemia, on the HIV virus. She was initially skeptical of the results, which showed a decrease in the number of infectious virus particles. She questioned this "eureka" moment, wondering if she had perhaps administered the test incorrectly. She had indeed conducted the test accurately, and further studies using AZT were quickly underway.
Just over 2 years later AZT was successfully released for patient use. Since then, St. Clair has worked tirelessly to research and bring to market effective treatments for HIV patients around the world. Repurposing, as demonstrated by research on the use of AZT for HIV more than 30 years ago, has proven to be an exciting and impactful way to fast-cycle treatments for both common and rare diseases.
Improving patient lives by accelerating medical repurposing research has been the cornerstone of Cures Within Reach for more than 10 years. "We are honored to acknowledge the incredible impact Marty St. Clair has had on HIV patients through her repurposing research by presenting her with the Janet Davison Rowley Patient Impact Research Award," said Bruce Bloom, President of Cures Within Reach.
By awarding her this prestigious honor, Cures Within Reach is recognizing the lifelong dedication of Marty St. Clair to finding effective treatments for this potentially devastating virus. "I appreciate being honored by Cures Within Reach for my research efforts and my commitment to making a meaningful difference in improving the lives of HIV patients," said Marty St. Clair.
Cures Within Reach advocates for the inclusion of drug repurposing in global initiatives addressing major world health concerns, such as the Open Source Pharma initiative, examining affordable open source development options to treat malaria, tuberculosis, and other neglected diseases.
Cures Within Reach will be awarding Patient Impact Awards to several other accomplished individuals at their gala event, including Dr. Nick Sireau and Professor Lakshminarayan Ranganath for their repurposing research related to Alkaptonuria or AKU, and Dr. Jerome Zeldis, CEO of Celgene Global Health and Chief Medical Officer of Celgene.
The 2016 Global Health Repurposing Awards are sponsored by Celgene Corporation, Takeda Pharmaceuticals, PricewaterhouseCoopers, Horizon pharma plc, Beecken Petty O'Keefe and Company, Rediscovery Life Sciences, Hulow Medical and many others.
For more information about the awards gala or to register for the event visit: http://cureswithinreach.org/
ABOUT CURES WITHIN REACH
Cures Within Reach works to catalyze repurposing research to quickly and affordably improve patient lives. We accomplish this through collaborations that connect researchers and funding, by facilitating crowd sourcing and community, and by identifying alternative financing models and incentives. Cures Within Reach's repurposing research projects have generated 13 "new" treatments making an impact through off-label use in clinical practice or through a commercialization track.
Cures Within Reach built CureAccelerator (www.CureAccelerator.org) to provide a global collaboration space and market for repurposing research that can deliver effective solutions to unsolved diseases. The CureAccelerator platform was built with a grant from the Robert Wood Johnson Foundation, to explore whether drugs, devices and nutraceuticals approved for one or more human diseases can be repurposed to create "new" treatments in other diseases. CureAccelerator has almost 1,000 users who have proposed over 100 projects, of which more than a dozen are already funded and moving towards patient impact.
Visit us at: www.cureswithinreach.org or follow us via Twitter.com/